Cargando…
Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations who was treated with the combination of the second‐generation TKI nilotinib and JAK1/JAK2 inhibitor ruxol...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871410/ https://www.ncbi.nlm.nih.gov/pubmed/36703773 http://dx.doi.org/10.1002/ccr3.6801 |
| _version_ | 1784877165389545472 |
|---|---|
| author | Huo, Li Xie, Jundan Wang, Qian Shen, Hongjie Ding, Zixuan Wen, Lijun Zeng, Zhao Xu, Yi Ruan, Changgeng Chen, Suning Xue, Mengxing |
| author_facet | Huo, Li Xie, Jundan Wang, Qian Shen, Hongjie Ding, Zixuan Wen, Lijun Zeng, Zhao Xu, Yi Ruan, Changgeng Chen, Suning Xue, Mengxing |
| author_sort | Huo, Li |
| collection | PubMed |
| description | Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations who was treated with the combination of the second‐generation TKI nilotinib and JAK1/JAK2 inhibitor ruxolitinib. |
| format | Online Article Text |
| id | pubmed-9871410 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98714102023-01-25 Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib Huo, Li Xie, Jundan Wang, Qian Shen, Hongjie Ding, Zixuan Wen, Lijun Zeng, Zhao Xu, Yi Ruan, Changgeng Chen, Suning Xue, Mengxing Clin Case Rep Case Report Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations who was treated with the combination of the second‐generation TKI nilotinib and JAK1/JAK2 inhibitor ruxolitinib. John Wiley and Sons Inc. 2023-01-23 /pmc/articles/PMC9871410/ /pubmed/36703773 http://dx.doi.org/10.1002/ccr3.6801 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Case Report Huo, Li Xie, Jundan Wang, Qian Shen, Hongjie Ding, Zixuan Wen, Lijun Zeng, Zhao Xu, Yi Ruan, Changgeng Chen, Suning Xue, Mengxing Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib |
| title | Insights from a rare myeloproliferative neoplasm with coexisting
BCR‐ABL1
fusion gene,
CALR,
and
TET2
mutations treated with nilotinib and ruxolitinib |
| title_full | Insights from a rare myeloproliferative neoplasm with coexisting
BCR‐ABL1
fusion gene,
CALR,
and
TET2
mutations treated with nilotinib and ruxolitinib |
| title_fullStr | Insights from a rare myeloproliferative neoplasm with coexisting
BCR‐ABL1
fusion gene,
CALR,
and
TET2
mutations treated with nilotinib and ruxolitinib |
| title_full_unstemmed | Insights from a rare myeloproliferative neoplasm with coexisting
BCR‐ABL1
fusion gene,
CALR,
and
TET2
mutations treated with nilotinib and ruxolitinib |
| title_short | Insights from a rare myeloproliferative neoplasm with coexisting
BCR‐ABL1
fusion gene,
CALR,
and
TET2
mutations treated with nilotinib and ruxolitinib |
| title_sort | insights from a rare myeloproliferative neoplasm with coexisting
bcr‐abl1
fusion gene,
calr,
and
tet2
mutations treated with nilotinib and ruxolitinib |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871410/ https://www.ncbi.nlm.nih.gov/pubmed/36703773 http://dx.doi.org/10.1002/ccr3.6801 |
| work_keys_str_mv | AT huoli insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT xiejundan insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT wangqian insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT shenhongjie insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT dingzixuan insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT wenlijun insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT zengzhao insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT xuyi insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT ruanchanggeng insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT chensuning insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib AT xuemengxing insightsfromararemyeloproliferativeneoplasmwithcoexistingbcrabl1fusiongenecalrandtet2mutationstreatedwithnilotinibandruxolitinib |